Allogene Therapeutics, Inc.

Pfizer Corporation

Cellectis

Thomas Charles Pertel

Barbra Johnson Sasu

Arvind Rajpal

Philippe Duchateau

Roman Galetto

Thomas John Van Blarcom

Tracy Chia-Chien Kuo

Javier Fernando Chaparro Riggers

Alexandre Juillerat

Cesar Adolfo Sommer

Bijan Andre Boldajipour

Julien Valton

Mark W Leonard

Laurent Poirot

Tao Sai

Donna Marie Stone

Shobha Chowdary Potluri

Diego A Vargas-inchaustegui

Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors

Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).

Methods of manufacturing allogeneic CAR T cells

The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Chimeric antigen receptors targeting B-cell maturation antigen

Polynucleotides encoding rituximab-resistant chimeric antigen receptors

The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.

Anti-TALEN antibodies and uses thereof

Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.

Antibodies against 4G7-derived chimeric antigen receptors

The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TXYXXX, wherein Xis an amino acid Xis an amino acid Xis an amino acid and Xis V or I.

Inhibitory chimeric antigen receptors

Growing community of inventors

San Mateo, CA, United States of America

Thomas Charles Pertel